What Is GHK-Cu? The Complete Guide to Copper Peptide Research
At age 20, the average person carries approximately 200 ng/mL of GHK-Cu in their plasma. By age 60, that figure has dropped to around 80 ng/mL, a decline of roughly 60% over four decades. What makes this observation particularly compelling to researchers is not the number itself but what it coincides with: a measurable reduction in tissue regenerative capacity, slower wound closure, thinning skin, and declining collagen density. The body produces GHK-Cu naturally, it declines precisely when it is most needed, and the scientific literature exploring what happens when it is restored has grown substantially over the past three decades.
GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring copper-binding tripeptide comprising three amino acids bound to a copper ion (Cu²⁺), first isolated from human plasma in 1973 by Dr Loren Pickart. It has since become one of the most extensively researched peptides in molecular biology, with studies linking it to collagen synthesis, wound healing, gene expression modulation, antioxidant activity, and tissue remodelling across multiple organ systems.
This guide covers the current state of GHK-Cu research, the mechanisms proposed in the literature, and how Vi Corpus supplies GHK-Cu for research purposes in Australia.
Structure and Chemistry
GHK-Cu is classified as a tripeptide, with three amino acids (glycine, histidine, lysine) connected in sequence and complexed with a divalent copper ion. Its molecular weight of 403.92 g/mol places it in the category of small, highly bioavailable signalling peptides that can interact with cell surface receptors and penetrate tissue barriers with relative ease.
| Property | Detail |
| Full name | Glycyl-L-histidyl-L-lysine copper(II) |
| Abbreviation | GHK-Cu |
| Molecular formula | C₁₄H₂₄CuN₆O₄ |
| Molecular weight | 403.92 g/mol |
| CAS number | 89030-95-5 |
| Peptide sequence | Gly-His-Lys |
| Form supplied | Lyophilised powder |
| Purity (Vi Corpus) | ≥98–99% |
GHK-Cu as a Natural Copper Modulator
One of the more nuanced aspects of GHK-Cu that the research literature emphasises is what it does not do: it does not flood tissue with copper. Instead, it functions as a copper chaperone, a carrier molecule that regulates where copper is delivered and which copper-dependent enzymes are activated as a result. This distinction matters because copper at high concentrations is cytotoxic, whereas copper delivered in precisely the right form to the right enzymatic sites drives tissue repair, antioxidant defence, and collagen crosslinking.
The three copper-dependent enzymes most associated with GHK-Cu activity are lysyl oxidase, which crosslinks collagen and elastin fibres to give connective tissue its tensile strength; superoxide dismutase (SOD), the primary antioxidant enzyme responsible for neutralising reactive oxygen species in tissue; and cytochrome c oxidase, a key component of the mitochondrial electron transport chain involved in cellular energy production. In each case, GHK-Cu research suggests the peptide acts as an enabling signal, a molecular “copper switch” that moves copper to where enzymatic activity is needed rather than accumulating it non-specifically.
Multiple Cellular Pathways: How GHK-Cu Works
The breadth of GHK-Cu’s proposed mechanisms in the scientific literature is unusual for a tripeptide of its size. What research suggests is not a single targeted action but a cascade of interconnected signalling events that collectively shift the cellular environment toward repair and regeneration.
Among the most studied mechanisms is GHK-Cu’s dual role in collagen metabolism. Research indicates the peptide simultaneously stimulates new collagen synthesis, including increased production of Type I and Type III collagen fibres, while also activating matrix metalloproteinases (MMPs), the enzymes responsible for breaking down damaged or disorganised extracellular matrix. This cleanup-and-rebuild mechanism is what distinguishes GHK-Cu from simple collagen stimulators: it does not just add new collagen on top of old; it helps clear dysfunctional matrix first, then rebuilds. In vitro studies suggest a similar dual action applies to elastin, with GHK-Cu research showing increased elastin gene expression alongside MMP-mediated matrix remodelling.
GHK-Cu has also been investigated for its role in fibroblast activation and migration, with fibroblasts being the primary cells responsible for producing collagen and extracellular matrix components in connective tissue. Research further indicates involvement in angiogenesis (new blood vessel formation), which supports oxygen and nutrient delivery to repair sites, and in nerve outgrowth stimulation, a finding that has attracted interest in neuroprotective research contexts. The anti-inflammatory activity observed in studies, particularly suppression of NF-κB and p38 MAPK signalling pathways, adds another layer, suggesting GHK-Cu may help regulate the inflammatory environment in which tissue repair occurs.
Gene Expression: A Regulatory Signal at Scale
Perhaps the most striking finding in GHK-Cu research is its apparent influence on gene expression at scale. Studies published in the journal Genome Medicine and subsequent analyses by Pickart and colleagues suggest GHK-Cu modulates the expression of over 4,000 human genes, upregulating repair-associated pathways while downregulating genes linked to inflammation, tissue degradation, and disease progression. To put that number in context, many pharmaceutical compounds are designed to interact with a single receptor or pathway; GHK-Cu, in vitro studies suggest, acts more like a broad regulatory signal.
The framing that researchers have used is that GHK-Cu pushes gene activity toward a “younger” or more regenerative state. Upregulated genes include those involved in extracellular matrix synthesis, fibroblast activation, skin remodelling, and DNA repair. Downregulated genes include those associated with inflammatory cytokine production, oxidative stress pathways, and matrix degradation. Research also indicates that GHK-Cu has activated over 400 genes specifically related to repair processes including collagen and elastin synthesis and fibroblast function.
It is important to note that much of this gene expression data derives from in vitro studies and bioinformatic analysis rather than controlled human trials, and the translation of these findings to in vivo outcomes remains an active area of investigation. The appropriate framing remains: in vitro studies suggest, research indicates, preclinical models demonstrate. These are not established clinical outcomes.
Wound Healing Research
Wound healing is the area with the longest research history for GHK-Cu, and the breadth of findings spans multiple wound types and tissue contexts. The core mechanisms proposed include enhanced fibroblast migration, increased blood vessel formation, collagen synthesis stimulation, and anti-inflammatory activity. Together these converge on the key phases of wound repair: inflammation resolution, proliferation, and matrix remodelling.
Open Wound Models
In wound chamber models using rats, a 1993 study demonstrated that GHK-Cu treatment resulted in significantly increased total protein and collagen synthesis compared to controls, providing early experimental evidence for its role in extracellular matrix accumulation at wound sites. Research has further shown that GHK-Cu improves wound contraction, stimulates granular tissue formation, and promotes angiogenesis, all of which are markers of effective healing in preclinical models.
Ischaemic Wound Research
Ischaemic wounds, where compromised blood supply limits oxygen delivery to tissue, present a more challenging healing environment. Research indicates GHK-Cu’s angiogenic properties may be particularly relevant here, with studies suggesting improved blood flow and vascular development in ischaemic wound models. The peptide’s ability to stimulate new blood vessel formation is proposed as a mechanism for improving oxygenation and nutrient availability at impaired wound sites.
Diabetic Wound Models
Diabetic wound healing is a significant area of unmet need in clinical medicine, and preclinical research has investigated GHK-Cu’s potential relevance. In a collagen dressing study using rats, GHK-Cu was shown to accelerate wound healing in both healthy and diabetic subjects, a finding that researchers have highlighted as suggesting effectiveness across wound types with different underlying biology. The mechanisms proposed involve enhanced fibroblast recruitment, improved collagen organisation, and reduced inflammatory cytokine activity in the wound environment.
COPD and Lung Tissue Research
One of the more clinically significant areas of GHK-Cu research, and one of the least discussed in Australian peptide content, involves chronic obstructive pulmonary disease (COPD) and lung tissue restoration. Research has demonstrated that GHK-Cu can restore normal function to lung fibroblasts obtained from COPD patients, suggesting the peptide may reverse cellular changes associated with disease progression at the fibroblast level. This finding is notable because COPD-associated fibroblasts typically show impaired repair capacity; the restoration of more normal function in vitro points to potential mechanisms worth investigating further.
Separately, bioinformatic analyses have explored GHK-Cu’s gene expression profile in the context of emphysema. Research suggests the peptide’s broad gene modulation activity may partially reverse expression signatures associated with lung tissue destruction, specifically the progressive loss of alveolar structure that characterises emphysema. Studies examining GHK-Cu’s influence on genes linked to extracellular matrix degradation and inflammatory signalling in lung tissue have produced findings that have attracted attention from researchers working in pulmonary fibrosis and COPD contexts.
As with other areas of GHK-Cu research, these findings are primarily derived from in vitro and bioinformatic studies. The translation to human clinical outcomes in COPD remains a subject of ongoing investigation. This is, however, one of the most cited research areas for GHK-Cu in the broader peptide science literature and represents a meaningful dimension of its proposed biology that goes well beyond skin and wound applications.
Emerging Neuroprotective Research
Preclinical research has begun exploring GHK-Cu in neurological contexts, including Alzheimer’s disease models and age-related cognitive decline. Animal studies have investigated the peptide’s effects on markers associated with amyloid plaque accumulation and cognitive function, with some models suggesting GHK-Cu may have potential relevance to neuroinflammation and neuroprotective pathways. Research also indicates possible effects on anxiety-related behaviour in animal models. These findings are early-stage and warrant cautious interpretation. They establish GHK-Cu as a subject of neuroprotective investigation rather than a demonstrated neurological therapy. For researchers working at the intersection of ageing biology and cognitive health, this is an emerging dimension of GHK-Cu’s proposed mechanisms worth monitoring as the literature develops.
Skin Regeneration and Anti-Ageing Research
The skin-related research on GHK-Cu is the most clinically advanced body of work for this peptide, with multiple human studies published across dermatology and cosmetic science journals. The mechanisms proposed in this context build directly on GHK-Cu’s core biology: collagen and elastin synthesis stimulation, MMP-mediated matrix remodelling, fibroblast activation, and antioxidant activity all converge on measurable markers of skin quality.
In a study involving 71 women with mild to advanced signs of photoaging, daily application of a facial cream containing GHK-Cu for three months resulted in increased skin density and thickness, reduced sagging, and a measurable decrease in the appearance of fine lines and wrinkles. Research has further demonstrated that GHK-Cu can significantly increase Type I collagen and elastin fibre levels in skin, contributing to improved texture and reduced visible signs of ageing. A pilot study confirmed improvements in skin thickness, elasticity, hydration, and collagen synthesis markers from topical GHK-Cu application.
Research also indicates that GHK-Cu enhances the production of protective barrier proteins in the skin and increases the expression of genes involved in collagen and elastin synthesis, effectively supporting extracellular matrix rebuilding at the gene expression level. These findings have informed GHK-Cu’s inclusion in the Klow blend, Vi Corpus’s four-peptide formulation designed for skin and recovery research applications.
Hair Follicle Research
GHK-Cu has been investigated for potential roles in hair follicle biology, with research exploring several proposed mechanisms. Studies suggest the peptide may stimulate fibroblasts in the scalp microenvironment and promote angiogenesis, improving blood circulation to hair follicles and thereby supporting nutrient and oxygen delivery necessary for follicle function. Research also indicates GHK-Cu may inhibit transforming growth factor beta (TGF-β), a signalling molecule associated with premature follicle miniaturisation, the progressive reduction in follicle size observed in androgenetic alopecia. By opposing TGF-β activity, GHK-Cu has been investigated as a potential modulator of follicle miniaturisation in male pattern baldness models. Additionally, research suggests the peptide may extend the anagen (active growth) phase of the hair cycle, allowing more time for hair shaft development before follicles enter the resting phase. These findings position GHK-Cu as a subject of active investigation in follicle stimulation research.
Antioxidant and Anti-Inflammatory Activity
GHK-Cu acts as a potent antioxidant through multiple proposed mechanisms. Its role as a copper chaperone for superoxide dismutase (SOD) supports the neutralisation of reactive oxygen species (ROS), unstable molecules that accumulate in damaged tissue and interfere with normal cellular repair. In a tissue repair context, ROS reduction matters because oxidative stress impairs fibroblast function, disrupts collagen synthesis, and prolongs the inflammatory phase of healing. By supporting SOD activity and reducing oxidative burden, GHK-Cu research suggests the peptide helps create a more favourable cellular environment for recovery.
The anti-inflammatory activity attributed to GHK-Cu involves suppression of two key signalling pathways: NF-κB and p38 MAPK. NF-κB is a master regulator of inflammatory gene expression; its inhibition reduces the production of pro-inflammatory cytokines that drive tissue damage when inflammation becomes chronic rather than acute. p38 MAPK is involved in cellular stress responses and inflammatory signalling cascades. Research indicates GHK-Cu’s downregulation of these pathways contributes to its observed ability to reduce inflammatory markers, calm skin irritation, and support the resolution of chronic low-grade inflammation, a factor increasingly associated with tissue ageing and impaired repair across organ systems.
GHK-Cu in the Vi Corpus Product Range
Vi Corpus supplies GHK-Cu as a standalone lyophilised research compound at 50mg per vial, with purity verified at ≥98–99% through independent third-party testing via Janoshik Analytical. The compound requires reconstitution prior to use and is supplied freeze-dried for stability during storage and transit.
GHK-Cu also appears in two Vi Corpus combination research products, reflecting its role as an extracellular matrix remodelling agent that complements the mechanisms of other peptides in the range.
The Wolverine Peptides Stack combines GHK-Cu with BPC-157 and TB-500, a research-oriented combination that has attracted significant interest in recovery biology. The logic behind the combination is mechanistic: BPC-157 research focuses on localised tissue repair signalling, particularly at musculoskeletal and gastrointestinal sites; TB-500 (Thymosin Beta-4) research centres on systemic cellular migration and actin regulation; GHK-Cu’s extracellular matrix remodelling role provides a third layer, supporting the structural scaffolding into which migrating repair cells organise. For detailed background, see the Wolverine Stack guide (link to be added once live).
Klow is Vi Corpus’s four-peptide blend formulated for skin and recovery research, containing GHK-Cu at 50mg within an 80mg total formulation. GHK-Cu’s collagen synthesis, skin barrier, and anti-ageing research profile makes it a core component of the Klow formulation.
Check Vi Corpus GHK-Cu for current stock, vial specifications, and ordering information.
Storage, Reconstitution, and Purity Verification
Vi Corpus GHK-Cu is supplied as a lyophilised (freeze-dried) powder, which maximises stability during shipping and extends shelf life when stored correctly. Lyophilised peptides should be stored at −20°C in a sealed, moisture-free environment. Once reconstituted, the solution should be refrigerated at 2–8°C and used within the timeframe appropriate for the reconstituting solution used.
Reconstitution requires bacteriostatic water, a sterile water solution containing a preservative (typically 0.9% benzyl alcohol) that inhibits microbial growth in multi-use vials. For guidance on reconstitution procedure and dosing calculations, see the Vi Corpus Peptide Reconstitution and Storage Guide and the Bacteriostatic Water posts. Using the correct reconstituting agent and maintaining sterile technique throughout are important for research integrity and compound stability.
Each batch of Vi Corpus GHK-Cu is independently verified for purity by Janoshik Analytical, a third-party laboratory. Certificates of analysis are accessible via the Janoshik verification portal, providing researchers with documented confirmation of purity prior to use. This independent verification is part of Vi Corpus’s commitment to supplying research-grade compounds with traceable quality documentation.
GHK-Cu Research: A Summary
GHK-Cu is one of the most extensively studied peptides in molecular biology, with a research profile spanning wound healing, collagen and elastin synthesis, gene expression modulation, antioxidant and anti-inflammatory activity, skin regeneration, hair follicle biology, lung tissue research, and emerging neuroprotective investigation. Its proposed biology is unusually broad for a tripeptide, a consequence, researchers suggest, of its role as a natural signalling molecule that the body uses to coordinate repair responses across multiple tissue types.
The decline of GHK-Cu in human plasma with age remains the central observation that drives scientific interest: a peptide the body already produces, falling to roughly 40% of youthful levels at precisely the age when regenerative capacity matters most. Whether restoring those levels through exogenous research compounds produces the outcomes suggested by the in vitro and animal literature is the question that continues to motivate investigation.
Frequently Asked Questions
What is the difference between GHK and GHK-Cu?
GHK refers to the tripeptide sequence alone, glycine, histidine, and lysine. GHK-Cu is the copper-bound form, in which the peptide is complexed with a divalent copper ion (Cu²⁺). The copper component is essential to the biological activity described in the research literature; GHK without copper does not activate the copper-dependent enzymatic pathways associated with GHK-Cu. The naturally occurring form found in human plasma is the copper-bound version.
How does GHK-Cu differ from BPC-157 and TB-500?
The three peptides operate through distinct proposed mechanisms and are studied in different, though potentially complementary, contexts. BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide investigated primarily for localised tissue repair, including musculoskeletal, gastrointestinal, and connective tissue healing. TB-500 (Thymosin Beta-4) is studied for its role in actin regulation and systemic cellular migration, with research focusing on its ability to mobilise repair cells to injury sites. GHK-Cu’s proposed role centres on extracellular matrix remodelling, stimulating collagen and elastin synthesis, clearing damaged matrix, and modulating the gene expression environment in which repair occurs. Together, the three are studied as complementary components of the Wolverine Peptides Stack.
What products contain GHK-Cu at Vi Corpus?
Vi Corpus supplies GHK-Cu in three forms: as a standalone lyophilised research compound (50mg, ≥98–99% purity); as a component of the Wolverine Peptides Stack alongside BPC-157 and TB-500; and as a component of Klow, the four-peptide blend formulated for skin and recovery research. All three are available via the Vi Corpus website and are supplied for research purposes only.
Does GHK-Cu need to be reconstituted before use?
Yes. Vi Corpus GHK-Cu is supplied as a lyophilised powder and must be reconstituted with bacteriostatic water before use. Reconstitution should be performed using sterile technique. For step-by-step guidance, refer to the Vi Corpus Peptide Reconstitution and Storage Guide. Once reconstituted, the solution should be stored at 2–8°C and handled according to standard research peptide protocols.
What is GHK-Cu studied for in research?
GHK-Cu is studied across a broad range of biological contexts, including wound healing and tissue repair, collagen and elastin synthesis, gene expression modulation (with in vitro studies suggesting influence over 4,000+ genes), skin regeneration and anti-ageing markers, hair follicle biology, antioxidant and anti-inflammatory activity, lung tissue restoration in COPD models, and emerging neuroprotective research in preclinical models. It is supplied by Vi Corpus for research purposes only and is not approved for human therapeutic use in Australia.
Disclaimer: GHK-Cu is supplied by Vi Corpus strictly for research and laboratory purposes. It is not approved for human therapeutic or veterinary use in Australia. This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. All research applications must comply with applicable regulations and institutional ethical guidelines. Consult a qualified medical professional before considering any peptide-based protocol.